Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GLPG vs EXEL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GLPG
Galapagos N.V.

Biotechnology

HealthcareNASDAQ • BE
Market Cap$1.83B
5Y Perf.-86.3%
EXEL
Exelixis, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$11.74B
5Y Perf.+87.0%

GLPG vs EXEL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GLPG logoGLPG
EXEL logoEXEL
IndustryBiotechnologyBiotechnology
Market Cap$1.83B$11.74B
Revenue (TTM)$1.11B$2.38B
Net Income (TTM)$321M$833M
Gross Margin56.0%71.6%
Operating Margin26.7%39.4%
Forward P/E4.9x14.0x
Total Debt$7M$173M
Cash & Equiv.$88M$482M

GLPG vs EXELLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GLPG
EXEL
StockMay 20May 26Return
Galapagos N.V. (GLPG)10013.7-86.3%
Exelixis, Inc. (EXEL)100187.0+87.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: GLPG vs EXEL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GLPG and EXEL are tied at the top with 3 categories each — the right choice depends on your priorities. Exelixis, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GLPG
Galapagos N.V.
The Income Pick

GLPG has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.

  • beta 0.74
  • Rev growth 303.5%, EPS growth 333.0%, 3Y rev CAGR 66.4%
  • Lower volatility, beta 0.74, Low D/E 0.2%, current ratio 20.15x
Best for: income & stability and growth exposure
EXEL
Exelixis, Inc.
The Long-Run Compounder

EXEL is the clearest fit if your priority is long-term compounding.

  • 8.3% 10Y total return vs GLPG's -41.9%
  • 35.1% margin vs GLPG's 28.9%
  • +25.5% vs GLPG's +7.5%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthGLPG logoGLPG303.5% revenue growth vs EXEL's 7.0%
ValueGLPG logoGLPGLower P/E (4.9x vs 14.0x)
Quality / MarginsEXEL logoEXEL35.1% margin vs GLPG's 28.9%
Stability / SafetyGLPG logoGLPGBeta 0.74 vs EXEL's 0.80, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)EXEL logoEXEL+25.5% vs GLPG's +7.5%
Efficiency (ROA)EXEL logoEXEL30.5% ROA vs GLPG's 8.3%, ROIC 32.1% vs 12.5%

GLPG vs EXEL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GLPGGalapagos N.V.
FY 2022
Upfront payments and milestone payments
66.6%$174M
Jyseleca
33.4%$88M
EXELExelixis, Inc.
FY 2025
Product, Gross
64.9%$3.0B
Product
45.7%$2.1B
License
4.6%$214M
Collaboration
4.3%$197M
Service
-0.4%$-17,053,000
Product, Sales Discounts And Allowances
-19.2%$-889,003,000

GLPG vs EXEL — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLEXELLAGGINGGLPG

Income & Cash Flow (Last 12 Months)

EXEL leads this category, winning 4 of 6 comparable metrics.

EXEL is the larger business by revenue, generating $2.4B annually — 2.1x GLPG's $1.1B. EXEL is the more profitable business, keeping 35.1% of every revenue dollar as net income compared to GLPG's 28.9%.

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
RevenueTrailing 12 months$1.1B$2.4B
EBITDAEarnings before interest/tax$244M$958M
Net IncomeAfter-tax profit$321M$833M
Free Cash FlowCash after capex-$266M$918M
Gross MarginGross profit ÷ Revenue+56.0%+71.6%
Operating MarginEBIT ÷ Revenue+26.7%+39.4%
Net MarginNet income ÷ Revenue+28.9%+35.1%
FCF MarginFCF ÷ Revenue-23.9%+38.7%
Rev. Growth (YoY)Latest quarter vs prior year+10.9%+10.0%
EPS Growth (YoY)Latest quarter vs prior year+40.0%+43.6%
EXEL leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

GLPG leads this category, winning 4 of 4 comparable metrics.

At 4.9x trailing earnings, GLPG trades at a 71% valuation discount to EXEL's 16.6x P/E. On an enterprise value basis, GLPG's 2.8x EV/EBITDA is more attractive than EXEL's 12.7x.

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
Market CapShares × price$1.8B$11.7B
Enterprise ValueMkt cap + debt − cash$1.7B$11.4B
Trailing P/EPrice ÷ TTM EPS4.87x16.62x
Forward P/EPrice ÷ next-FY EPS est.13.96x
PEG RatioP/E ÷ EPS growth rate0.32x
EV / EBITDAEnterprise value multiple2.75x12.68x
Price / SalesMarket cap ÷ Revenue1.40x5.06x
Price / BookPrice ÷ Book value/share0.48x6.03x
Price / FCFMarket cap ÷ FCF13.90x
GLPG leads this category, winning 4 of 4 comparable metrics.

Profitability & Efficiency

EXEL leads this category, winning 6 of 8 comparable metrics.

EXEL delivers a 40.2% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $11 for GLPG. GLPG carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXEL's 0.08x. On the Piotroski fundamental quality scale (0–9), EXEL scores 7/9 vs GLPG's 6/9, reflecting strong financial health.

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
ROE (TTM)Return on equity+11.2%+40.2%
ROA (TTM)Return on assets+8.3%+30.5%
ROICReturn on invested capital+12.5%+32.1%
ROCEReturn on capital employed+14.2%+35.0%
Piotroski ScoreFundamental quality 0–967
Debt / EquityFinancial leverage0.00x0.08x
Net DebtTotal debt minus cash-$81M-$309M
Cash & Equiv.Liquid assets$88M$482M
Total DebtShort + long-term debt$7M$173M
Interest CoverageEBIT ÷ Interest expense11.29x
EXEL leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

EXEL leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in EXEL five years ago would be worth $18,403 today (with dividends reinvested), compared to $3,695 for GLPG. Over the past 12 months, EXEL leads with a +25.5% total return vs GLPG's +7.5%. The 3-year compound annual growth rate (CAGR) favors EXEL at 34.4% vs GLPG's -12.9% — a key indicator of consistent wealth creation.

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
YTD ReturnYear-to-date-15.9%+6.0%
1-Year ReturnPast 12 months+7.5%+25.5%
3-Year ReturnCumulative with dividends-34.0%+142.8%
5-Year ReturnCumulative with dividends-63.0%+84.0%
10-Year ReturnCumulative with dividends-41.9%+833.5%
CAGR (3Y)Annualised 3-year return-12.9%+34.4%
EXEL leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — GLPG and EXEL each lead in 1 of 2 comparable metrics.

GLPG is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than EXEL's 0.80 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXEL currently trades 93.1% from its 52-week high vs GLPG's 73.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
Beta (5Y)Sensitivity to S&P 5000.74x0.80x
52-Week HighHighest price in past year$37.78$49.62
52-Week LowLowest price in past year$24.74$33.76
% of 52W HighCurrent price vs 52-week peak+73.4%+93.1%
RSI (14)Momentum oscillator 0–10046.367.6
Avg Volume (50D)Average daily shares traded165K2.7M
Evenly matched — GLPG and EXEL each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates GLPG as "Hold" and EXEL as "Buy". Consensus price targets imply 19.0% upside for GLPG (target: $33) vs -1.1% for EXEL (target: $46).

MetricGLPG logoGLPGGalapagos N.V.EXEL logoEXELExelixis, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$33.00$45.71
# AnalystsCovering analysts2432
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+8.1%
Insufficient data to determine a leader in this category.
Key Takeaway

EXEL leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GLPG leads in 1 (Valuation Metrics). 1 tied.

Best OverallExelixis, Inc. (EXEL)Leads 3 of 6 categories
Loading custom metrics...

GLPG vs EXEL: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is GLPG or EXEL a better buy right now?

For growth investors, Galapagos N.

V. (GLPG) is the stronger pick with 303. 5% revenue growth year-over-year, versus 7. 0% for Exelixis, Inc. (EXEL). Galapagos N. V. (GLPG) offers the better valuation at 4. 9x trailing P/E, making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GLPG or EXEL?

On trailing P/E, Galapagos N.

V. (GLPG) is the cheapest at 4. 9x versus Exelixis, Inc. at 16. 6x.

03

Which is the better long-term investment — GLPG or EXEL?

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +84. 0%, compared to -63. 0% for Galapagos N. V. (GLPG). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus GLPG's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GLPG or EXEL?

By beta (market sensitivity over 5 years), Galapagos N.

V. (GLPG) is the lower-risk stock at 0. 74β versus Exelixis, Inc. 's 0. 80β — meaning EXEL is approximately 8% more volatile than GLPG relative to the S&P 500. On balance sheet safety, Galapagos N. V. (GLPG) carries a lower debt/equity ratio of 0% versus 8% for Exelixis, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — GLPG or EXEL?

By revenue growth (latest reported year), Galapagos N.

V. (GLPG) is pulling ahead at 303. 5% versus 7. 0% for Exelixis, Inc. (EXEL). On earnings-per-share growth, the picture is similar: Galapagos N. V. grew EPS 333. 0% year-over-year, compared to 58. 0% for Exelixis, Inc.. Over a 3-year CAGR, GLPG leads at 66. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GLPG or EXEL?

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus 28. 9% for Galapagos N. V. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GLPG leads at 45. 1% versus 37. 6% for EXEL. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GLPG or EXEL more undervalued right now?

Analyst consensus price targets imply the most upside for GLPG: 19.

0% to $33. 00.

08

Which pays a better dividend — GLPG or EXEL?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is GLPG or EXEL better for a retirement portfolio?

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +833. 5% 10Y return). Both have compounded well over 10 years (EXEL: +833. 5%, GLPG: -41. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GLPG and EXEL?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLPG is a small-cap high-growth stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GLPG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 546%
  • Net Margin > 17%
Run This Screen
Stocks Like

EXEL

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 21%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GLPG and EXEL on the metrics below

Revenue Growth>
%
(GLPG: 1093.2% · EXEL: 10.0%)
Net Margin>
%
(GLPG: 28.9% · EXEL: 35.1%)
P/E Ratio<
x
(GLPG: 4.9x · EXEL: 16.6x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.